Reversing autism by targeting downstream mTOR signaling.
about
Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesAlterations in sociability and functional brain connectivity caused by early-life seizures are prevented by bumetanide.Genetic aspects of autism spectrum disorders: insights from animal modelsFMRP S499 is phosphorylated independent of mTORC1-S6K1 activity.Autism Spectrum Disorders and Schizophrenia Spectrum Disorders: Excitation/Inhibition Imbalance and Developmental Trajectories.Oxytocin modulates markers of the unfolded protein response in Caco2BB gut cellsHippocampal HDAC4 contributes to postnatal fluoxetine-evoked depression-like behavior.Fragile X mental retardation protein: from autism to neurodegenerative disease.Autism spectrum disorders: emerging mechanisms and mechanism-based treatment.Lipopolysaccharide Exposure Induces Maternal Hypozincemia, and Prenatal Zinc Treatment Prevents Autistic-Like Behaviors and Disturbances in the Striatal Dopaminergic and mTOR Systems of OffspringNeurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism.Lipid rafts: a signaling platform linking cholesterol metabolism to synaptic deficits in autism spectrum disorders.Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders.New experimental treatments for core social domain in autism spectrum disorders.The use of stem cells to study autism spectrum disorderTranscriptomic profiling of mTOR and ryanodine receptor signaling molecules in developing zebrafish in the absence and presence of PCB 95.
P2860
Q27023257-6FCDCB9F-A6DD-4C09-89D4-955AE70B5611Q27308078-ADD33FED-1247-46C8-8F32-07EAB9B58D4DQ27687011-D25F87CF-5D36-41CE-B2BC-C31DB8F2B8F5Q33578330-0F550615-0F66-4121-A7DD-5384C16F7B4BQ33619607-0BE8E7E9-C698-416E-AD04-7B6B84637E92Q33700829-CA38E21A-767C-4111-B709-345DDC4172BFQ33923651-87AAE03E-D112-474F-9F34-F63B9C1CAEE5Q35077291-9CFB7E32-D641-4506-9467-241EF14E36B1Q35595728-31E4CE91-9C2C-40CC-9622-EDAA921C8DDFQ35719523-1B839F7F-8A31-4C06-96F1-A913822A0405Q37417949-68A95DC1-931B-4246-B8A8-216BFD061E7FQ37681389-7BB5B8FF-C99E-4406-A3C0-C5686EC2D32CQ38193084-AB306D6C-D4D7-4434-9412-9F33B6EFB253Q38226820-E26DF006-44C1-41AB-BBFE-097F5400D576Q38368547-BB9ADC75-61DB-45BC-94D3-B0D4908AF735Q46248754-983C8D41-29B7-426C-9CDB-0276157EADB8
P2860
Reversing autism by targeting downstream mTOR signaling.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Reversing autism by targeting downstream mTOR signaling.
@ast
Reversing autism by targeting downstream mTOR signaling.
@en
type
label
Reversing autism by targeting downstream mTOR signaling.
@ast
Reversing autism by targeting downstream mTOR signaling.
@en
prefLabel
Reversing autism by targeting downstream mTOR signaling.
@ast
Reversing autism by targeting downstream mTOR signaling.
@en
P2860
P356
P1476
Reversing autism by targeting downstream mTOR signaling.
@en
P2093
Hansen Wang
Laurie C Doering
P2860
P356
10.3389/FNCEL.2013.00028
P577
2013-03-26T00:00:00Z